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Abstract 
This review discusses the rapidly evolving field of immunotherapy research, focusing on the types of 
cancer antigens that can be recognised by the immune system and potential methods by which 
neoantigens can be exploited clinically to successfully target and clear tumour cells. Recent studies 
suggest that the likelihood of successful immunotherapeutic targeting of cancer will be reliant on 
immune response to neoantigens. This type of cancer specific antigen arises from somatic variants 
that result in alteration of the expressed protein sequence. Massively parallel sequencing techniques 
now allow the rapid identification of these genomic mutations and algorithms can be used to predict 
those that will be processed by the proteasome, bind to the transporter complex and encode peptides 
that bind strongly to individual MHC molecules. The emerging data from assessment of the 
immunogenicity of neoantigens suggests that only a minority of mutations will form targetable 
epitopes and therefore the potential for immunotherapeutic targeting will be greater in cancers with 
a higher frequency of protein altering somatic variants. It is evident that neoantigens contribute to 
the success of some immunotherapeutic interventions and that there is significant scope for specific 
targeting of these antigens to develop new treatment approaches.  
 
Key points: 
This review discusses the types of cancer antigens that can be recognised by the immune system and 
the method by which these antigens are shown to the immune cells. 
The focus is then drawn to the neoantigen classification of tumour antigen and methods by which this 
can be clinically targeted.  
This review concludes with the current challenges and future goals of targeting neoantigens in the 
treatment of cancer. 
 
1 Introduction 
Since the hypotheses was put forward by Paul Ehrlich at the start of the 20th century that the immune 
system can control the development of tumourigenic cells [1], researchers have been striving to 
understand the nature of this control, how it fails and how to manipulate it to clear tumour cells. 
Enthusiasm and focus on the immune control of cancer has gone through significant peaks and troughs 
in the intervening 100 years and is currently undergoing a significant resurgence (for reviews on the 
history of immunotherapy, references [1-3] are recommended). Thanks to technological advances, 
researchers are now able to molecularly characterise tumours and responding immune cells. This has 
led to breakthroughs including the identification of pharmacologically targetable immune suppression 
markers and a greater understanding of the immune targets displayed by cancer cells, which is the 
subject of this review. 
The importance of many subsets of cells within the immune system to the surveillance, recognition 
and removal of cancer cells has been uncovered and significant research has been undertaken to 
attempt to manipulate these cell types to promote cancer clearance (excellent reviews discussing the 
interplay of immune cells involved in the “elimination, equilibrium and escape” of tumour cells are: 
[4-6]). Immune cells that can recognise cancer cells as being different to ‘self’, include CD4+ and CD8+ 
T-cells and B-cell subsets. This review will focus on the immune targets displayed by cancer cells to be 
recognised by T-cells; a recommended review of the role of B cells in tumour recognition and immune 
suppression is by Yuen et al [7]. 
1.1 Types of antigens displayed by cancer cells 
Broadly, there are four main types of immune targets displayed by cancer cells (known as ‘antigens’): 
1. Tumour associated antigens: Processed fragments of proteins that are normally expressed at low 
levels in the cell, but are over expressed in cancer cells, often due to genomic amplification. Examples 
include ERBB2 in breast cancer [8], CD19 in B-cell malignancies [9] and tyrosinase in melanomas [10]. 
2. Cancer/Testis (CT) antigens: Derived from proteins usually only expressed by reproductive tissues 
(e.g. testes, foetal ovaries and placenta) and have limited/no expression in all other adult tissues. As 
normal reproductive cells do not display antigens [11], CT epitopes are considered to be fairly cancer 
specific. Examples include MAGE [12] and NY-ESO-1 [13]; a comprehensive list and evaluation of CT 
antigens are available at http://www.cta.lncc.br/ (Ludwig Institute for Cancer Research). 
3. Viral antigens: Some cancers are associated with viral infection, such as the human papilloma virus 
and cervical or oropharyngeal cancers [14, 15]. The proteins encoded by the viral open reading frames 
within the cell can be processed and displayed on the cancer cells, making this a cancer specific 
antigen. 
4. Neoantigens/neoepitopes: This classification of antigen is the result of a mutation in a protein 
coding region that occurs in a non-germline cell after birth, first identified in a murine models [16, 17]. 
Such somatic mutations accumulate in the cancer cell during the initiation, development and 
metastasis of the tumour. When the mutated protein product is processed by the cell and the peptide 
fragment containing this mutation is displayed, it can be recognised as ‘non-self’ by the immune 
system, stimulating an anti-tumour response. 
Many in vitro, in vivo and clinical trial studies have been carried out focusing on tumour antigens from 
the first three classifications to understand their utility as targets for immunotherapy. These 
approaches work on the assumption that a given tumour type is likely to display certain antigens and 
targeting them has resulted in tumour regression and/or complete response in some patients. The 
response rates were, however, consistently low, despite many different methods of raising an immune 
response to these three types of antigen being investigated [18]. 
The seminal work of Lennerz et al in 2005 demonstrated a high degree of individuality in the anti-
tumour immune response and that the predominant antigen responses uncovered were against 
mutated neoepitopes [19]. This was followed up by Segal et al, who used early next generation 
sequencing data from breast and colorectal cancer [20] as the basis for neoantigen prediction, 
concluding that there was a “gold mine” of potential for targeting immunogenic peptides created from 
both ‘driver’ and ‘passenger’ somatic variants [21]. Prior to the advent of whole genome/exome 
sequencing, the method to identify neoepitopes was by labour-intensive individual cDNA library 
screening (e.g. as performed in [19]) and as a result, the number of identified and studied neoantigens 
was fairly low. Massively parallel sequencing has become a mainstay technique (reviewed in [22]), 
meaning that tumour specific genetic mutations affecting protein coding regions can be rapidly 
identified, which has facilitated the prediction of neoepitopes. This has boosted the interest in the use 
of these neoantigens for personalised immunotherapy.  
1.2 MHC protein processing 
All vertebrates express MHC (major histocompatibility complex) on the majority of their cells, which 
sample peptide fragments within, or outside, the cell to alert the immune system to infection by 
pathogens. This process requires T-cells to distinguish ‘self’ from ‘non-self’; the MHC complexes 
display peptides from all protein sources and if the T-cells recognise ‘self’ peptide, there is a risk of 
autoimmunity. In humans, the proteins are encoded by genes in a cluster on chromosome 6. They are 
broadly split into two types: MHC-class I and MHC-class II molecules. Humans have three classical 
MHC-class I genes, called HLA-A, HLA-B and HLA-C and three classical MHC-class II molecules: HLA-DR, 
HLA-DQ and HLA-DP; non-classical MHC molecules also exist. CD8+ T cells recognise internal protein-
derived peptides displayed on MHC-class I molecules, while CD4+ T cells recognise externally derived 
peptides bound to MHC-class II. 
Both MHC-class I and –class II genes have significant population variation, with polymorphisms 
resulting in amino-acid differences particularly concentrated in the region that binds the processed 
peptides. This results in different binding strengths to the same peptides being conferred by these 
individual genotypes. There are now thousands of different HLA alleles identified in the human 
population, which results in considerable population variety in the peptides that can bind. The 
structure that binds the peptide consists of a groove formed by two anti-parallel -helices overlaying 
an eight-strand -sheet. An important difference between MHC-class I and MHC-class II is in the 
binding groove positioning of the peptide; in MHC-class I, the peptide is confined at both the N- and 
C-termini, while for MHC-class II the peptides are not restricted by the groove and can overhang. This 
has important consequences for prediction algorithms for which peptides can bind to molecules of 
each type. Receptors on the T-cell can recognise and bind the MHC molecule-peptide complex. 
Comprehensive reviews on the structure of the MHC molecules (e.g. [23]) and recognition by T-cells 
of the MHC-peptide complex (e.g. [24]) are available, which provide a greater depth of insight into the 
intricacies of these processes.  
The immune recognition by T-cells can be broadly considered as a two-part process where-by: 1) the 
protein has to be cleaved within the proteasome into the specific peptides [25] capable of binding to 
the TAP (transporter associated with antigen processing) complex for selective movement of peptides 
to the endoplasmic reticulum for processing [26] and to the specific HLA molecule (dictated by the 
MHC polymorphic variations in the population) 2) the T-cell receptor is able to recognise the HLA 
bound peptide.  
1.3 Cancer antigen immune recognition 
The key to the recognition of cancer cells by the immune system is distinguishing between ‘self’ and 
‘non-self’. Viral antigens and mutated peptide neoantigens are more likely to be sufficiently different 
to ‘self’ to stimulate a significant immune response than those antigens derived from over- or 
restricted- tissue expression. Indeed, the affinity of the T-cell receptor and subsequent strength of the 
immune response to the former type of epitopes tends to be stronger than those seen for the latter 
[27, 28]. The viral, over-expression and CT antigens have the advantage over neoantigens that a single 
epitope is more likely to be shared between individuals with the same HLA allele. The neoepitope 
approach is dictated by the combination of tumour mutation and HLA restriction and is therefore more 
likely to be a personalised therapy; although notable exceptions do exist, where the neoepitope is 
formed from more common mutations important in the tumourigenic process. 
1.4 Identification of neoantigens 
1.4.1 Types of neoantigen 
Neoantigens can arise from any genomic mutation that occurs in the cancer cell that results in an 
alteration in the sequence of an expressed protein. These can include non-synonymous mutations 
(e.g. [19, 29]), retained introns (e.g. [30]), post-translational modification that alters amino acid 
(e.g.[31]), gene fusions (e.g. [32]) and frameshift in/del variants (e.g. [33]). Attempts have been made 
to use mass spectrometry methodology to directly identify the peptides bound to the MHC-class I 
molecules on the membranes of cancer cells, with varying degrees of success; indeed, while thousands 
of peptides can be identified, neoantigens are only rarely detected [34-42]. Prior to the advent of 
massively parallel sequencing, the main screening method for finding neoantigens was cDNA 
expression libraries, which was very labour intensive (e.g. as described in Lennerz et al [19]). Other 
efforts focused on common driver mutations, to investigate if the combination of mutated 
peptide/HLA type was immunogenic; this has included BRAF [43, 44], KRAS [45, 46], p53 [47] and NRAS 
[48]. 
1.4.2 Prediction of neoantigen in the era of next generation sequencing technology 
The ability to rapidly identify tumour specific genetic variants has enabled researchers to attempt to 
predict the immunogenic epitopes created. Firstly, integration of mRNA expression data to the 
mutation information, using either whole genome microarrays (e.g. [29]) or RNA-seq (e.g. [49, 50]), is 
required in order to identify which of the mutated genes are transcribed. The mutations in expressed 
genes are then taken forward for epitope prediction using algorithms specific for HLA-alleles. This 
requires the amino acid sequence to be translated from the surrounding genetic sequence. A 
confounding factor is population polymorphism, which if in phase with the somatic variant may 
additionally alter amino acids from the reference sequence; working directly from sequencing data 
allows this to be taken into consideration. Examples of epitope prediction algorithms include 
SYFPEITHI [51], RANKPEP [52], NetMHCpan [53], NetMHCcons [54], PickPocket [55], MHCflurry (in pre-
print, https://doi.org/10.1101/174243), ANN [56] and SMM [57]. The algorithms have been trained 
using characterised epitope/MHC combinations, which have allowed consensus sequence to be 
identified and predict likelihood of binding ability of short peptide sequences. These algorithms have 
differing capabilities of identifying epitopes that bind to HLA-alleles, influenced by the training set. As 
a result, the less common HLA-alleles tend to have higher binding scores (e.g. as assessed in [29, 34]), 
which means that using a standard threshold to indicate “strong” binding is currently likely to miss 
potential neoepitopes binding to rarer HLA-alleles. As more studies identify and functionally examine 
the peptides binding to HLA-alleles are carried out, the more robust these analyses will become; the 
current interest in this field is significantly increasing available data. Bioinformatic pipelines have been 
created that use whole genome/exome sequencing data and integrate the analysis to include HLA 
allele typing, mRNA expression data, peptide processing prediction and HLA allele binding for the 
wildtype and mutated peptide. These include pVAC-seq [58], TIminer [59], Cloudneo [60] and MuPeXi 
[61].Testing of neoantigen immunogenicity 
Taking the data from the prediction algorithms, there are a number of methods by which 
immunoreactive neoepitopes can be identified. These include screening of the predicted peptides 
across mixed lymphocyte-tumour culture (MLTC) (e.g. [19, 29]), exposure of tandem mini-genes (e.g. 
[62-66]) or pMHC multimers (e.g. [50, 67, 68]) to immune cells, and the pulsing of putative peptides 
with antigen presentation cells (such as dendritic cells or B-cells) and co-culture with T-cells, followed 
by T-cell exposure to predicted peptide pools (e.g. [69]). These approaches can identify existing 
memory T-cell immune responses in patients, or reactive naïve T-cells in patients/donors, which have 
potential clinical utility. 
1.5 MHC-class II restricted neoantigens 
The role of the TH1 subset of CD4+ T-cells in priming, supporting, recruiting and proliferation of CD8+ T-
cells is well established; however other CD4+ T-cells subsets (e.g. TH2 and Treg) might promote tumour 
cell survival when activated. [70] Immunoreactive MHC-class II restricted neoantigens recognised by 
CD4+ T-cells have been described (e.g. [64, 71-73]; reviewed in [70]) and have been shown to elicit a 
clinically relevant response when immunotherapeutically targeted [62]. In order for MHC-class II 
restricted neoantigens to be clinically applicable on a large scale, more reliable prediction of the 
peptides that will bind to MHC-class II and a better understanding of the factors influencing CD4+ 
subset activation are required. 
2 Immunotherapeutic potential of neoantigens 
From the recent studies of neoantigens it is clear that only a minority of somatic variants create an 
immunogenic antigen (e.g. [29, 50, 66, 71, 74-79]). This means that the cancer types with a higher 
genomic mutation burden are more likely to form neoantigens, as there are more opportunities for 
one to be produced [71, 74, 78, 80-82]. Additionally, the presence of neoantigen(s) has been shown 
to contribute to the success of the checkpoint immunotherapies (targeting PD-1/PD-L1/CTLA4) (e.g. 
[50, 75, 83]) and other forms of immunotherapy, including dendritic cell vaccines (e.g. unpublished 
observations and [29], assessing patients from these clinical trials [84, 85]) and adoptive T-cell transfer 
(e.g. [86, 87]). Additionally, many studies have assessed the potential influence of neoantigens on 
overall survival and/or therapeutic success, without performing functional assessment of the immune 
response, including neoantigen fitness models that predicts tumour response to checkpoint blockade 
immunotherapy (e.g. [78, 88]) and in silico assessment of genomic data predicting neoantigen burden 
(e.g. [74-76, 80, 89]). Together, these data suggest that the likelihood of successful 
immunotherapeutic targeting of neoantigens will be greater in cancers with a higher frequency of 
protein altering somatic variants, but was not sufficient to predict clinical benefit. 
Since the earlier work of Lennerz et al [19], the identification of neoantigens eliciting dominant 
immune responses capable of initiating tumour clearance has continued, which has encouraged 
researchers to target them therapeutically. The approaches used to date will be outlined in the 
following sections. 
2.1 CAR-modified T cells 
Chimeric antigen receptors (CAR) are synthetic molecules designed to direct T cells to recognise 
specific antigens. CAR-modified T-cells are an autologous method of overcoming tolerance and have 
been successfully used in the treatment of B cell malignancies, with the cells directed to the over-
expressed CD19 molecule [90-92]. It is extremely important for CAR-modified T-cells to only be 
directed towards surface antigens confined to the cancer cell, to avoid serious off-target effects and 
toxicities (e.g. [93, 94]) and is a significant limitation of this approach. The direction of CAR-modified 
T-cells against neoepitopes has been examined. An example of this is the cancer specific epidermal 
growth factor variant III (EGFRvIII), which is caused by an in-frame deletion of exons 2-7, resulting in 
constitutively activation of EGFR signalling [95]. Cancers with this variant present include 
glioblastomas and head and neck squamous cell carcinoma [96, 97]. CAR-modified T-cell therapies 
against this neoepitope [98] are currently in clinical trial (e.g. NCT01454596 and NCT02209376), for 
which the results are eagerly anticipated. The advantage of targeting EGFRvIII is that it is a common 
‘driver’ mutation in certain solid cancers and therefore the production of these CAR-modified T-cells 
can be applied to a high proportion of patients.  
Individually engineered CAR-modified T-cells against neoantigens is plausible if the T-cell receptor 
recognising the HLA-bound peptide is known or can be predicted (the possibility is further discussed 
in the reviews: [99, 100]). The potential of unpredictable off-target effects due to cross-reactivity, 
where the engineered T-cell receptor recognises other displayed antigens, cannot currently be 
anticipated [101]. Together with the additional intensive manufacturing that would be required for 
each patient’s personalised therapy means it is unlikely this approach will be used routinely in the 
near future, but pose intriguing research subjects of investigation. 
2.2 Adoptive T-cell transfer 
Adoptive T-cell transfer in the treatment of cancer involves the in vitro selection and expansion of 
tumour reactive lymphoctyes, which are grown under conditions aimed to overcome the tolerisation 
that exists in vivo. As the selection and expansion occurs in vitro, it is possible to modify the host 
immune setting and/or the reactive cells before cell transfer back into the patient. Examples of this 
approach being clinically implemented are the isolation, expansion and transfer of HLA-DPB1*04:01 
restricted NY-ESO-1 reactive CD4+ T-cells, derived from the peripheral blood of a melanoma patient, 
which resulted in prolonged clinical remission [102] and the isolation and expansion of autologous 
tumour infiltrating lymphocytes (TIL) from melanoma patients, which were reinfused back into 
patients who had undergone lymphodepletion, in the presence of interleukin 2 (IL-2), resulting in 
~20% complete durable response [103-105].  
Adoptive T-cell transfer is also highly amenable to focus on neoepitope reactive T-cells. Indeed, 
adoptive T-cell transfer of neoantigen reactive cells has been trialled in the clinical setting. This 
includes the identification of polyclonal CD8+ T-cells reactive against a neoepitope restricted through 
HLA-C*08:02 derived from the KRAS mutation p.G12D in TIL from a patient with colorectal cancer, 
which was expanded and transferred back into the patient, resulting in tumour regression [86]. In this 
patient, a metastatic deposit stopped responding and upon analysis, the mechanism of resistance was 
identified as the loss of the HLA-C*08:02 allele [86]. Another example was the screening of TIL from 
lung metastasis in a patient with cholangiocarcinoma, using a mini-gene construct that encoded each 
of the 26 non-synonymous tumour specific mutations, which identified reactivity to a p.E805G 
mutation in ERBB2IP, restricted through HLA-DQB1*06:01 and recognised by CD4+ TH1 cells. Following 
expansion of these cells, adoptive transfer in the presence of IL-2 resulted in a halt of tumour 
progression and disease stabilisation. A lung metastasis stopped responding and the process was 
repeated with TIL from the progressing tumour, focusing on polyfunctional (IFN, TNF- and IL-2 
producing) neoepitope reactive cells, which again resulted in tumour regression and stabilisation [62]. 
The identification of autologous reactive T-cells is not always possible using the currently available 
methods. Therefore, research has also investigated the possibility of using donor T-cells that recognise 
patient specific neoepitopes for adoptive T-cell transfer. A feasibility study found reactivity to 11 
predicted neoepitopes from two HLA-A*02:01 stage IV melanoma in donor blood cells, using 
monocyte derived dendritic cells transfected with candidate epitopes in a mini-gene, followed by 
analysis with pMHC multimers. Results from a third melanoma patient did not yield any reactive cells 
from donor blood for the chosen predicted neoepitopes [67]. These results therefore indicate there is 
scope to use non-autologous T-cells for targeting individual neoantigens in future therapies for some 
patients. 
2.3 Other potential avenues for immunotherapeutic treatments with neoantigens 
Other possible approaches to target cancer antigens either attempt to reinvigorate an identifiable 
existing but supressed immune response, or try to initiate naïve reactivities to potentially displayed 
neoepitope(s). These include therapeutic vaccination with recombinant viral vectors encoding tumour 
specific antigen (e.g. as reviewed in [106]), vaccination with recombinant proteins/peptides, with 
adjuvants (e.g. [107] and as reviewed in [108, 109]), dendritic cell vaccines, primed with specific 
antigens (e.g. [42] and as reviewed in [110]) and RNA based poly-epitope vaccines [111]. While these 
approaches have been significantly explored for CT and over-expression antigens, there still remains 
significant scope to explore these options targeting neoantigens. A major lesson from these previous 
trials is that these approaches are generally well tolerated, providing scope for combinations of 
treatments to attempt to overcome resistance mechanisms. A search of currently registered clinical 
trials revealed a significant number (at the time of writing n=~40) that include a neoantigen 
component. This includes the combination of personalised neoepitope DNA vaccine with anti-PD-1 
checkpoint inhibition (e.g. NCT03199040, triple negative breast cancer; NCT02950766, renal cell 
carcinoma), dendritic cell vaccine raised against defined neoepitopes (e.g. NCT03300843, melanoma, 
gastrointestinal, breast, ovarian and pancreatic cancers) and adjuvant personalised neoantigen 
peptide vaccine, with the immunostimulant poly-ICLC (e.g. NCT02510950, glioblastoma and 
astrocytoma and NCT01970358, melanoma). The immunotherapy field has been moving rapidly in 
recent years and these clinical trials will continue pushing the field forwards. 
3 Challenges and future opportunities 
There are several important challenges to overcome and key basic immunological questions that 
require answering before neoantigens are exploited to their full potential. One of the obstacles is the 
‘personalised’ nature of the therapy, which requires each tumour to be sequenced and results 
analysed for each individuals HLA genotypes; the therapy of choice is then manufactured specifically 
for each patient. Work is being carried out to automate this process further, however, with patients 
urgently awaiting treatment upon diagnosis, the time to perform analysis and manufacture compared 
to ‘off the shelf’ options are still of considerable consideration. Tumour heterogeneity is also an 
important factor to overcome. As previously reviewed [18], immunotherapy targeting multiple 
antigens have a higher objective response rate than those focused on a single epitope. When a single 
target is the focus of a therapy, resistance is also more likely, an example of which was previously 
discussed, where the restricting HLA-C allele of the epitope target was selectively deleted in a 
metastatic deposit [86].  
In order to fully exploit neoepitopes, a better understanding is required of: a) the reason why certain 
sequences are more likely to be processed and displayed on MHC-class I or MHC-class II molecules 
and b) what factors control mutated proteins are processed and shuttled to the lymph nodes for 
interrogation by antigen presenting cells stimulate CD8+ and/or CD4+ T-cells. The increased 
identification of immunoreactive neoantigens and the characterisation of the tumour context in which 
they occur will begin to address these fundamental questions. Additionally, the binding prediction 
algorithms for MHC-class II are still considered to be relatively imprecise, which given the success of 
recent clinical studies specifically targeting the neoantigen specific CD4+ immune response in patients 
[43, 62, 71, 102], is a significant area requiring improvement. 
Finally, mechanisms of resistance to immunotherapies include loss of MHC alleles from the gene 
cluster on chromosome 6, loss of expression of HLA support molecules (such as β2-microglobulin and 
CIITA), loss of expression of the antigen target(s) and a hostile tumour microenvironment (the recent 
review by Sharma et al [112] explores these mechanisms in detail). In order for immunotherapies to 
produce a durable complete response, it is important that the molecular mechanisms driving 
resistance methods are characterised, to identify strategies that prevent or circumnavigate them. It is 
highly likely that future treatment regimens will involve combination of therapy types and further 
research into synergistic drug combinations is a current research priority. 
4 Concluding remarks 
The immunotherapy field is currently undergoing a significant resurgence in popularity due to the 
identification of antibodies that can target the immune checkpoint markers PD-1 and CTLA4 on Treg 
cells and PD-L1 on cancer cells. The blocking of suppressive immune cells allows a reinvigorated anti-
cancer immune response, which seems to be largely targeting neoepitopes. This classification of 
antigen can be independently predicted and confirmed, allowing a combination of 
immunotherapeutic approaches to be trialled in order to improve survival time and overall durability 
of the response. While there are still many avenues to explore in this field, the pace at which research 
is being performed and translated into clinical trials is remarkable and are leading to ever improving 
outcomes for patients. 
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